First‐in‐human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males

Por Moschetti, Viktoria, Boland, Katja, Feifel, Ulrich, Hoch, Anja, Zimdahl‐Gelling, Heike, Sand, Michael
Publicado no Br J Clin Pharmacol (2016)

Pharmacokinetics, Safety, and Tolerability of Faldaprevir in Patients with Renal Impairment

Por Huang, Fenglei, Moschetti, Viktoria, Lang, Benjamin, Halabi, Atef, Petersen-Sylla, Marc, Yong, Chan-Loi, Elgadi, Mabrouk
Publicado no Antimicrob Agents Chemother (2014)

Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies

Por Norris, Stephen, Ramael, Steven, Ikushima, Ippei, Haazen, Wouter, Harada, Akiko, Moschetti, Viktoria, Imazu, Susumu, Reilly, Paul A., Lang, Benjamin, Stangier, Joachim, Glund, Stephan
Publicado no Br J Clin Pharmacol (2017)

Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover P...

Por Glund, Stephan, Stangier, Joachim, van Ryn, Joanne, Schmohl, Michael, Moschetti, Viktoria, Haazen, Wouter, De Smet, Marina, Gansser, Dietmar, Norris, Stephen, Lang, Benjamin, Reilly, Paul, Kreuzer, Jörg
Publicado no Clin Pharmacokinet (2016)